Commit To Purchase Ennis At $15, Earn 4.5% Annualized

Investors eyeing a purchase of Ennis Inc (EBF) shares, but tentative about paying the going market price of $17.68/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2014 put at the $15 strike, which has a bid at the time of this writing of 45 cents. Collecting that bid as the premium represents a 3% return against the $15 commitment, or a 4.5% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Selling a put does not give an investor access to EBF's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $15 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Ennis Inc sees its shares decline 15.3% and the contract is exercised (resulting in a cost basis of $14.55 per share before broker commissions, subtracting the 45 cents from $15), the only upside to the put seller is from collecting that premium for the 4.5% annualized rate of return.

Interestingly, that annualized 4.5% figure actually exceeds the 4% annualized dividend paid by Ennis Inc, based on the current share price of $17.68. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to fall 15.35% to reach the $15 strike price.

Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Ennis Inc, looking at the dividend history chart for EBF below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 4% annualized dividend yield.

EBF+Dividend+History+Chart

Below is a chart showing the trailing twelve month trading history for Ennis Inc, and highlighting in green where the $15 strike is located relative to that history:

Loading+chart++2013+TickerTech.com

The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the April 2014 put at the $15 strike for the 4.5% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Ennis Inc (considering the last 250 trading day closing values as well as today's price of $17.68) to be 24%. For other put options contract ideas at the various different available expirations, visit the EBF Stock Options page of StockOptionsChannel.com.

In mid-afternoon trading on Wednesday, the put volume among S&P 500 components was 626,907 contracts, with call volume at 626,907, for a put:call ratio of 0.75 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today.

null

More from Stocks

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Why Spotify Is the Ultimate Speculative Stock to Buy

Why Spotify Is the Ultimate Speculative Stock to Buy

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data